BRAF-Mutant NSCLC 
BRAF mutations have been identified in 2% of patients with NSCLC, half of whom have a BRAF V600E mutation. In these patients, the response rate was 63.2%, and median PFS was 9.7 months after treatment with a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib[68].A response rate of 42% and median PFS of 7.3 months were reported after treatment with vemurafenib, another BRAF inhibitor [69].These data strongly recommend using targeted therapy to treating patients with BRAF-mutant lung cancer for better clinical outcomes .